Therapeutic areas: Oncology, Dermatology
Incyte reps are anchored by Jakafi (ruxolitinib) in myelofibrosis and polycythemia vera, plus Opzelura (ruxolitinib cream) in dermatology for atopic dermatitis and vitiligo. Biosimilar pressure on Jakafi is a growing conversation, while Opzelura represents a significant commercial expansion into derm.
Key products: Jakafi, Opzelura, Pemazyre, Zynyz
Incyte reps are anchored by Jakafi (ruxolitinib) in myelofibrosis and polycythemia vera, plus Opzelura (ruxolitinib cream) in dermatology for atopic dermatitis and vitiligo. Biosimilar pressure on Jak